Boston Scientific Emerging Markets — Net Sales increased by 0.9% to $772.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 15.6%, from $668.00M to $772.00M. Over 4 years (FY 2021 to FY 2025), Emerging Markets — Net Sales shows an upward trend with a 20.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market penetration and rising adoption of medical technologies in developing regions, while a decrease may signal competitive pressure, economic volatility, or regulatory hurdles in those territories.
This metric represents the total revenue generated from the sale of medical devices and services within designated high-...
Peers in the medical device industry typically report this as a component of international or regional revenue, often benchmarked against total global sales growth rates.
bsx_segment_emerging_markets_net_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $359.00M | $354.00M | $399.00M | $390.00M | $427.00M | $454.00M | $444.00M | $529.00M | $592.00M | $594.00M | $595.00M | $648.00M | $680.00M | $684.00M | $668.00M | $690.00M | $758.00M | $765.00M | $772.00M |
| QoQ Change | — | -1.4% | +12.7% | -2.3% | +9.5% | +6.3% | -2.2% | +19.1% | +11.9% | +0.3% | +0.2% | +8.9% | +4.9% | +0.6% | -2.3% | +3.3% | +9.9% | +0.9% | +0.9% |
| YoY Change | — | — | — | — | +18.9% | +28.2% | +11.3% | +35.6% | +38.6% | +30.8% | +34.0% | +22.5% | +14.9% | +15.2% | +12.3% | +6.5% | +11.5% | +11.8% | +15.6% |